Methylphosphinic Acid
Star0
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Methylphosphinic Acid
- DrugBank Accession Number
- DB02845
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 80.023
Monoisotopic: 80.002715916 - Chemical Formula
- CH5O2P
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism AAcetylcholinesterase inhibitorHumans ACholinesterase inhibitorHumans UEsterase Not Available Streptomyces scabies - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol Methylphosphinic Acid may increase the bradycardic activities of Acebutolol. Acetylcholine The risk or severity of adverse effects can be increased when Methylphosphinic Acid is combined with Acetylcholine. Aclidinium Methylphosphinic Acid may increase the neuromuscular blocking activities of Aclidinium. Amantadine The therapeutic efficacy of Amantadine can be decreased when used in combination with Methylphosphinic Acid. Amifampridine The risk or severity of adverse effects can be increased when Methylphosphinic Acid is combined with Amifampridine. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as organophosphorus compounds. These are organic compounds containing the phosphorus atom.
- Kingdom
- Organic compounds
- Super Class
- Organophosphorus compounds
- Class
- Not Available
- Sub Class
- Not Available
- Direct Parent
- Organophosphorus compounds
- Alternative Parents
- Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
- Substituents
- Aliphatic acyclic compound / Hydrocarbon derivative / Organic oxide / Organic oxygen compound / Organophosphorus compound / Organopnictogen compound
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- 4206-94-4
- InChI Key
- BCDIWLCKOCHCIH-UHFFFAOYSA-N
- InChI
- InChI=1S/CH5O2P/c1-4(2)3/h4H,1H3,(H,2,3)
- IUPAC Name
- methylphosphinic acid
- SMILES
- CP(O)=O
References
- Synthesis Reference
Hans-Jerg Kleiner, "Process for the preparation of halo-methylphosphinic acid halides." U.S. Patent US3943170, issued October, 1965.
US3943170- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) -40.01 °C PhysProp boiling point (°C) 162.6 °C PhysProp - Predicted Properties
Property Value Source Water Solubility 691.0 mg/mL ALOGPS logP -1.2 ALOGPS logP -1.2 Chemaxon logS 0.94 ALOGPS pKa (Strongest Acidic) 2.31 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 37.3 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 15.95 m3·mol-1 Chemaxon Polarizability 6.18 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.7111 Blood Brain Barrier + 0.9274 Caco-2 permeable - 0.571 P-glycoprotein substrate Non-substrate 0.8526 P-glycoprotein inhibitor I Non-inhibitor 0.9738 P-glycoprotein inhibitor II Non-inhibitor 0.9942 Renal organic cation transporter Non-inhibitor 0.9352 CYP450 2C9 substrate Non-substrate 0.7495 CYP450 2D6 substrate Non-substrate 0.8721 CYP450 3A4 substrate Non-substrate 0.7325 CYP450 1A2 substrate Non-inhibitor 0.8709 CYP450 2C9 inhibitor Non-inhibitor 0.8852 CYP450 2D6 inhibitor Non-inhibitor 0.9339 CYP450 2C19 inhibitor Non-inhibitor 0.9053 CYP450 3A4 inhibitor Non-inhibitor 0.9655 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9687 Ames test Non AMES toxic 0.5121 Carcinogenicity Carcinogens 0.7391 Biodegradation Not ready biodegradable 0.811 Rat acute toxicity 1.8580 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8678 hERG inhibition (predictor II) Non-inhibitor 0.961
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-01q9-9000000000-4196c9ae4092949a71d2 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-9000000000-ab19d378f4f872a3221f Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-001i-9000000000-b0c54a4ad1295d191ed9 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-03di-9000000000-7796e1243ba28abf4460 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-03di-9000000000-74fee3d314d08973aa5d Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-03di-9000000000-3c76f3936f62d9c97b50 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-03di-9000000000-39cd11fa2b53e5b0a714 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 118.66897 predictedDeepCCS 1.0 (2019) [M+H]+ 120.56438 predictedDeepCCS 1.0 (2019) [M+Na]+ 128.72762 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsAcetylcholinesterase
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Hydrolyzes rapidly the acetylcholine neurotransmitter released into the synaptic cleft allowing to terminate the signal transduction at the neuromuscular junction. Role in neuronal apoptosis
- Specific Function
- acetylcholine binding
- Gene Name
- ACHE
- Uniprot ID
- P22303
- Uniprot Name
- Acetylcholinesterase
- Molecular Weight
- 67795.525 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
2. DetailsCholinesterase
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters
- Specific Function
- acetylcholinesterase activity
- Gene Name
- BCHE
- Uniprot ID
- P06276
- Uniprot Name
- Cholinesterase
- Molecular Weight
- 68417.575 Da
References
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
Enzymes
1. DetailsCholinesterase
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters
- Specific Function
- acetylcholinesterase activity
- Gene Name
- BCHE
- Uniprot ID
- P06276
- Uniprot Name
- Cholinesterase
- Molecular Weight
- 68417.575 Da
References
- Dahl AR, Hobbs CH, Marshall TC: The inhibition of rat and guinea pig cholinesterases by anionic hydrolysis products of methylphosphonic difluoride (difluoro). Toxicol Appl Pharmacol. 1986 Jul;84(3):561-6. doi: 10.1016/0041-008x(86)90261-9. [Article]
Drug created at June 13, 2005 13:24 / Updated at August 26, 2024 19:22